These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 27619650)

  • 1. CRISPR as a driving force: the Model T of biotechnology.
    Mariscal C; Petropanagos A
    Monash Bioeth Rev; 2016 Jun; 34(2):101-116. PubMed ID: 27619650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA fragment editing of genomes by CRISPR/Cas9.
    Li JH; Shou J; Wu Q
    Yi Chuan; 2015 Oct; 37(10):992-1002. PubMed ID: 26496751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Progress in CRISPR/Cas9 Technology.
    Mei Y; Wang Y; Chen H; Sun ZS; Ju XD
    J Genet Genomics; 2016 Feb; 43(2):63-75. PubMed ID: 26924689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The application of CRISPR/Cas9 in genome editing of filamentous fungi.
    Li HH; Liu G
    Yi Chuan; 2017 May; 39(5):355-367. PubMed ID: 28487268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted Gene Manipulation in Plants Using the CRISPR/Cas Technology.
    Zhang D; Li Z; Li JF
    J Genet Genomics; 2016 May; 43(5):251-62. PubMed ID: 27165865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diversity and evolution of class 2 CRISPR-Cas systems.
    Shmakov S; Smargon A; Scott D; Cox D; Pyzocha N; Yan W; Abudayyeh OO; Gootenberg JS; Makarova KS; Wolf YI; Severinov K; Zhang F; Koonin EV
    Nat Rev Microbiol; 2017 Mar; 15(3):169-182. PubMed ID: 28111461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiplex gene editing by CRISPR-Cpf1 using a single crRNA array.
    Zetsche B; Heidenreich M; Mohanraju P; Fedorova I; Kneppers J; DeGennaro EM; Winblad N; Choudhury SR; Abudayyeh OO; Gootenberg JS; Wu WY; Scott DA; Severinov K; van der Oost J; Zhang F
    Nat Biotechnol; 2017 Jan; 35(1):31-34. PubMed ID: 27918548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intellectual property education exemplified by the patents on the CRISPR/Cas9 system.
    Fan X; Liao G; Xie J
    Yi Chuan; 2014 Dec; 36(12):1269-73. PubMed ID: 25487273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research progress in the third-generation genomic editing technology - CRISPR/Cas9].
    Zhou Y; Zong Y; Kong X
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2016 Oct; 33(5):713-6. PubMed ID: 27577230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA Regulation of Clinical Applications of CRISPR-CAS Gene-Editing Technology.
    Grant EV
    Food Drug Law J; 2016; 71(4):608-33. PubMed ID: 29140647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9 system as an innovative genetic engineering tool: Enhancements in sequence specificity and delivery methods.
    Jo YI; Suresh B; Kim H; Ramakrishna S
    Biochim Biophys Acta; 2015 Dec; 1856(2):234-43. PubMed ID: 26434948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inducible CRISPR genome-editing tool: classifications and future trends.
    Dai X; Chen X; Fang Q; Li J; Bai Z
    Crit Rev Biotechnol; 2018 Jun; 38(4):573-586. PubMed ID: 28936886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ji Luo Elucidates the CRISPR Gene Editing Technology, and How It May Affect Cancer Therapy in the Future.
    Luo J
    Oncology (Williston Park); 2016 Oct; 30(10):879. PubMed ID: 27753053
    [No Abstract]   [Full Text] [Related]  

  • 14. Exploring the potential of genome editing CRISPR-Cas9 technology.
    Singh V; Braddick D; Dhar PK
    Gene; 2017 Jan; 599():1-18. PubMed ID: 27836667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted genome editing in the rare actinomycete Actinoplanes sp. SE50/110 by using the CRISPR/Cas9 System.
    Wolf T; Gren T; Thieme E; Wibberg D; Zemke T; Pühler A; Kalinowski J
    J Biotechnol; 2016 Aug; 231():122-128. PubMed ID: 27262504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genome editing comes of age.
    Kim JS
    Nat Protoc; 2016 Sep; 11(9):1573-8. PubMed ID: 27490630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas9: From a bacterial immune system to genome-edited human cells in clinical trials.
    Kick L; Kirchner M; Schneider S
    Bioengineered; 2017 May; 8(3):280-286. PubMed ID: 28287876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [CRISPR-Cas system as molecular scissors for gene therapy].
    Heinz GA; Mashreghi MF
    Z Rheumatol; 2017 Feb; 76(1):46-49. PubMed ID: 28124743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of the genome editing tool CRISPR/Cas9 in non-human primates.
    Luo X; Li M; Su B
    Dongwuxue Yanjiu; 2016 Jul; 37(4):214-9. PubMed ID: 27469252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.